Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Arg16His

Meiling Luo, MD,1 Donghong Deng, MD,2 Liqun Xiang, MD,1 Peng Cheng, MD,2 Lin Liao, MD,1 Xuelian Deng, MD,1 Jie Yan, MD,1 Faquan Lin, MD1,∗

Abstract
Congenital dysfibrinogenemia (CD) is a qualitative fibrinogen disorder caused by an abnormal fibrinogen molecule structure, leading to dysfunctional blood coagulation. This study describes 3 cases of dysfibrinogenemia identified in the unrelated Chinese pedigrees. Routine coagulation screening tests were performed on the probands and their families. The antigens and functionality of fibrinogen was measured using an immunoturbidimetry assay and the Clauss method, respectively. To identify the genetic mutation responsible for these dysfibrinogens, genomic DNA extracted from the blood was analyzed using PCR amplification and direct sequencing. The presence of the mutant chains was determined using matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectroscopy. Purified plasma fibrinogen of 3 probands was analyzed using SDS-PAGE, fibrinogen clottability, fibrin polymerization, fibrinopeptide release, and scanning electron microscopy (SEM). The 3 probands had a long thrombin time. Levels of functional fibrinogen were found to be very low, while the fibrinogen antigen was within the normal range. DNA sequencing revealed a heterozygous Arg16His substitution in the fibrinogen α chain (FGA). The mutant chains were found to be expressed using MALDI-TOF mass spectroscopy. SDS-PAGE did not reveal any difference in the molecular weights of 3 polypeptide chains between normal and abnormal fibrinogens. Fibrinogen clottability showed a slower fibrin clot formation than the healthy control. Fibrin polymerization, after addition of thrombin, showed a prolonged lag phase and decreased final turbidity. The kinetics of fibrinopeptides release revealed a decreased amount of the released fibrinopeptide A, SEM of the patient’s fibrin clot was found to be abnormal. Results indicate that the 3 probands with dysfibrinogenemia were caused by mutations of α chain Arg16His. Mutation of this fibrinogen induced dysfunction of plasma fibrinogen.

Keywords: α Arg16His, dysfibrinogenemia, fibrinogen, fibrinopeptide A, missense mutation

1. Introduction
Fibrinogen, a 340kDa plasma glycoprotein, is synthesized predominantly in the liver and secreted into the blood circulation at a concentration of approximately 200 to 400 mg/dL, with a half-life of about 4 days.[1] It has a 2-fold axis of symmetry perpendicular to the long axis, which consists of 2 sets of 3 polypeptide chains (αα, ββ, γγ), and each half molecule are joined together in the N-terminal to form the domain central E domain.[2] The molecule is stabilized by 29 disulfide bonds. The core structure consists of 2 outer D domains and a central E domain connected through coiled connectors.[3] The D domains are made up of the globular C-termini of the Bβ and γ chains, and the C-termini of the αα chains fold back toward the central E domain.[4] The N-terminal regions of the αα and Bβ chains are cleaved during the release of fibrinopeptides. The 3 chains are encoded by paralogous genes FGA, FGB, and FGG (coding for αα, Bβ, and γγ chains, respectively), clustered in a 30kb region on chromosome 4 (4q31.3).[5] The FGA gene, composed of 6 exons spanning 7.5kb, is located between FGG (10 exons, 8.5kb) and FGB (8 exons, 8kb). FGB is transcribed in the opposite direction to FGA and FGG.[6]

Congenital dysfibrinogenemia (CD) is a qualitative fibrinogen disorder caused by an abnormal fibrinogen molecule structure, leading to blood coagulation dysfunction. Many studies show
that 1 characteristic of CD is normal fibrinogen antigen levels associated with disproportionately low functional activity.\(^\text{[7,8]}\)

The vast majority of cases are the result of heterozygous missense mutations in coding region of 1 of the 3 fibrinogen genes (FGA, FGB, or FGG).\(^\text{[9]}\) Molecular defects are usually single-base mutations, leading to alterations in the release of fibrinopeptide, fibrin polymerization, fibrin cross-linking, or fibrinolysis of the fibrinogen.\(^\text{[10]}\) At least 400 different dysfibrinogenemia pedigrees have been reported worldwide.\(^\text{[11]}\) Its prevalence is difficult to establish because of a large number of unreported asymptomatic cases.\(^\text{[12]}\)

Many studies have confirmed that over half of dysfibrinogenemias are asymptomatic, 25% hemorrhage, and 20% thrombosis.\(^\text{[13]}\) In fact, most asymptomatic patients with CD are fortuitously diagnosed during routine laboratory examination, similar to the 55% reported by Haverkate and Samama\(^\text{[14]}\) and the 48% reported by Shapiro et al.\(^\text{[15]}\) The clinical management of patients with genetically confirmed CD was challenging.\(^\text{[16]}\) In this respect, asymptomatic patients with the predisposing genotype are at risk of developing adverse outcomes during the natural course of the disease, so it is worthwhile to determine whether the thrombotic, hemorrhagic, abortion, or surgery-related risks associated with disproportionately low functional activity.\(^\text{[7,8]}\)

2. Materials and methods

2.1. Collection of blood

A final volume of 9 mL of blood from healthy volunteers and patients was drawn by venipuncture to 1mL of 3.8% trisodium citrate (pH 7.4). Plasma was obtained by blood centrifugation at 3000 rpm for 15 minutes. All individuals tested agreed to this study at the time of blood collection and provided an informed consent form. The control plasma from the healthy donors is an individual plasma.

2.2. Routine coagulation screening tests

Routine coagulation screening tests, including tests of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and clotting factors (VII, VIII, IX, XI, and XII) were performed with citrated plasma samples on an ACL TOP 700 coagulation analyzer (Instrumentation Laboratory, Bedford). The functional fibrinogen level in plasma was measured using a Clauss assay. A Human Fibrinogen ELISA kit (CUSABIO, Wuhan, China) was used to measure the antigen fibrinogen level.

2.3. Isolation and purification of fibrinogen

Plasma obtained from the patient was separated by centrifuging twice at 3000 rpm for 15 minutes, and then re centrifuged after dilution with an equal volume of 0.09 M sodium citrate. Protein was precipitated by adding saturated ammonium sulfate at pH 5.5 to 25% saturation at room temperature. After 70 minutes, the precipitate was harvested by centrifugation at 4°C. It was washed 3 times with 1 M ammonium sulfate, each time in a volume approximately equal to twice the original plasma volume. After the third wash, the precipitate was dissolved in 0.005 M sodium citrate and reprecipitated with ammonium sulfate (25% saturation). This precipitate was washed once in 1 M ammonium sulfate and redissolved in 0.005 M sodium citrate.

2.4. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)

The samples were suspended in 1×Tris–HCl treatment buffer (0.125 mol L\(^{-1}\) Tris–HCl, 4% SDS, 20% v/v glycerol, 0.2 mol L\(^{-1}\) DTT, 0.02% bromphenol blue, pH 6.8), boiled for 3 minutes to cleave noncovalent bonds, and briefly centrifuged. The molecular weight of the purified fibrinogen was determined by SDS–PAGE using 8% (w/v) stacking gels and 10% (w/v) polyacrylamide separating gels. After electrophoresis, the gel was stained with Coomassie Brilliant Blue G-250, then destained with a methanol/glacial acetic acid/distilled water solution (4:1:5 by volume). A low-range protein marker kit (Genei, Chennai, India) was used for calibration.\(^\text{[17]}\) All gels included a broad range standard mixture (Bio-Rad, Hercules, US) for molecular weight markers.

2.5. Fibrinogen clottability

Fibrinogen of either the patients or healthy donors was clotted in citrated plasma with addition at a concentration of 10 mmol/L EDTA, mix and then added at a final concentration of 20 NIHU/mL thrombin. After a 60 minutes incubation at 37°C, clots were washed in 50 mmol/L TRIS buffer (pH 7.4) 5 times and dissolved in 300 g/L urea. The fibrinogen concentration in urea was measured at 280 nm.

2.6. Fibrin polymerization curves measurement

The plasma fibrinogen level was adjusted to 0.5 g/L with a 50 mM TRIS 0.1 M NaCl 2.5 mM CaCl\(_2\) buffer (pH 7.4). Then 90 μL of a

| Table 1 |
| Coagulation screening results of family I. | Clotting time, s | Fibrinogen, g/L |
| --- | --- | --- |
| PT | APTT | Thrombin time | Reptilase time | Clauss | ELISA |
| --- | --- | --- | --- | --- | --- |
| I-1 | 14.3 | 34.8 | 21.3 | 53 | 0.78 | 3.56 |
| I-2 | 13.2 | 36.5 | 12.7 | 15 | 3.27 | 4.01 |
| I-3 | 14.1 | 34.8 | 11.8 | 16 | 3.04 | 3.24 |
| I-4 | 12.1 | 34.5 | 27.8 | 50 | 0.62 | 3.59 |
| I-5 | 13.8 | 36.3 | 13.1 | 19 | 3.93 | 4.10 |
| I-6 | 12.5 | 35.9 | 19.7 | 47 | 0.75 | 3.41 |
| Normal range | 9–15 | 23–40 | 9–15 | 14–25 | 2–5 | 2–5 |

APTT = activated partial thromboplastin time. PT = prothrombin time.
diluent of fibrinogen (0.5 g/L) was incubated with human thrombin (0.1 NIHU/mL, final concentration) at room temperature. The time-dependent increase in turbidity induced by the clot formation was measured continuously at intervals of 20 seconds for 20 minutes at 365 nm using ELISA reader Ceres 900 (Bio-tek Instruments, Winooski, VT), as described earlier.[22]

2.7. Polymerase chain reaction and DNA sequencing
Genomic DNA was extracted from fresh blood samples in ethylenediaminetetraacetic acid using standard procedures. The purified genomic DNA was amplified by polymerase chain reaction (PCR) using specific primers comprising all exons of the FGA, FGB, and FGG genes. Then PCR products were sequenced bidirectionally using standard Sanger dye terminator sequencing on an ABI 3730XL sequencer (Applied Biosystems, Grand Island, NY). After identification of the causative mutation, the probands’ family members were genotyped for the mutation.[23]

2.8. Kinetic measurement of release of fibrinopeptides
Reactions were performed in a final volume of 225 µL. Briefly, fibrinogen (0.22 mg/mL, final concentration) was mixed with N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] (HEPES) pH 7.4 (20 mM, final concentration), NaCl (0.12 mM, final concentration), and CaCl₂ (1 mM, final concentration). The release of fibrinopeptide was measured as a function of time: aliquots of the mixture were incubated with human thrombin (0.02 NIHU/mL, final activity) at room temperature for 0, 1, 3, 5, 10, 20, 30, and 60 minutes, respectively. The reaction was stopped by boiling for 5 minutes. The mixture was centrifuged twice at 17,000 rpm for 30 minutes at 4°C; and the concentration of fibrinopeptides in the supernatant were determined using a Human Fibrinopeptide A (FpA) ELISA kit and Human Fibrinopeptide B (FpB) ELISA kit (Cusabio, Shanghai, China) performed on Tecan Sunrise Elx-808 (BioTek, Shenzhen, China).

2.9. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)
MALDI-TOF MS was performed on an AB SCIEX TOF/TOF 4800 PLUS System (Bruker Daltonics, Bremen, Germany). The samples were prepared by mixing 1 µL of purified peptide solution and 2 µL of matrix solution [15 mg/mL of 2,5-dihydroxybenzoic acid in acetonitrile: 0.1% TFA (1:2)]. Then 1 µL of this mixture was placed on a stainless steel probe plate and allowed to dry at room temperature. The spectra of fibrinogen peptides were conducted in positive reflector mode in the range from 500 to 4000 Da.

2.10. Scanning electron microscopy (SEM) of fibrin clots
Fibrin clots were induced to form directly in a microwell plate by addition of 1 µL human thrombin (3 NIHU/mL, final concentration) to 33 µL plasma from either the patient or a healthy donor, and the clotting mixture was incubated at room temperature for 120 minutes. The clots were washed 3 times with 0.1 mol/L PBS (pH 7.4) and fixed with 3% glutaraldehyde in the same buffer for 4°C overnight, then dehydrated in a graded series of ethanol (50%, 70%, 80%, 90%, and 100% concentrations) twice. After the 100% ethanol step, samples were immersed in hexamethyldisilazane 3 times, followed by air-drying overnight in a fume hood. The clots were mounted on aluminum stubs and sputter-coated with 10 nm gold. Fibrin clots were examined by field emission scanning electron microscope (Tescan, Brno, Czech Republic), as described previously.[15]
Figure 1. Proteins were separated on SDS–PAGE using 8% (w/v) stacking gels and 10% (w/v) polyacrylamide separating gels under nonreducing condition. Lanes 1, 2, 3, and 4 correspond to fibrinogen precipitated from plasma of proband I-1, proband II-1, proband III-1, and a healthy control individual, respectively.

Figure 2. Thrombin-induced fibrin polymerization curves. Plasma samples of patients and health control were incubated with 0.9 NIH U/mL thrombin (final concentration), and measured every 20 seconds at 365 nm. OD = optical density.

Figure 3. DNA sequencing of the exon 2 of FGA. (A–C) Heterozygous point mutation G→A was found at the fibrinogen Aα gene of the patients changing the triplet CGT (Arg) to CAT (His). (D) Sequence of healthy control.
3. Results

3.1. Patients and routine coagulation tests

In family I, the proband was a 44-year-old man (I-1) with a low fibrinogen level as indicated by the Clauss method (0.78 g/L). He had specifically prolonged TT (21.3 seconds), but his fibrinogen antigen, which was detected using ELISA was not low at all (3.58 g/L, Table 1). His coagulation factors (VIII, IX, XI:C, and XII:C) were all within the normal ranges. He had no evidence of bleeding tendencies or thrombosis. His 64-year-old mother (I-4) also presented with a low functional fibrinogen level and prolonged TT, as did his children (I-6). Other families had normal coagulation test results (Table 1).

In family II, fibrinogen variants were a 30-year-old woman (II-1), her 6-year-old daughter (II-2), and her 60-year-old father. The proband (II-1) reported hematuria in 2014, but no extraordinary bleeding was observed during her cesarean section. Immuno-turbidimetrically determined fibrinogen level was 3.93 g/L and Clauss fibrinogen level was 0.72 g/L. She had no any previous episode of abnormal hemostasis. No member of the family has experienced bleeding, thrombosis, or spontaneous abortion. The results of their coagulation tests are shown in Table 2.

In family III, the proband (III-1) was an 89-year-old man whose laboratory data were compatible with the diagnosis of CD. Prolonged thrombin and low fibrinogen levels detected using the Clauss method were also observed in his 60-year-old son (III-3) and his grandson (III-6). No exceptional bleeding was observed during his 2 minor surgeries and 1 tooth extraction. There was no family history of thrombosis or bleeding tendency (Table 3).

Liver functions and platelet count of all these participants were normal. Neither of these patients had any consanguineous marriage.

3.2. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

SDS-PAGE did not reveal any detectable differences in the electrophoretic mobility between the probands of 3 families and healthy controls (Fig. 1). The molecular weights of the Aα, Bβ, and γ-chains of abnormal fibrinogen were found to be identical to those of normal fibrinogen.

3.3. Fibrinogen clottability

The clottability of propositus’ fibrinogen is reduced in comparison with the healthy control. The clottability of family I, II, III fibrinogen was found to be 67%, 61%, 64%, respectively. The clottability of the healthy control was found to be 98%.

3.4. Fibrin polymerization curves

The turbidity curve represents the kinetics of fibrin formation following the addition of thrombin, which was monitored turbidimetrically at 365 nm. Compared with the healthy control, the polymerization curve induced by thrombin for the probands showed a prolonged lag phase and a decreased final turbidity. The maximum turbidity of the probands at 20 minutes was less than the healthy control (Fig. 2).

3.5. DNA analysis

DNA sequencing of 3 families revealed a heterozygous point mutation in exon 2 of the FGA gene at the position c.104 G→A (Fig. 3A–C), which causes the substitution of Aα16Arg to His. The sequence numbering in this study refers to genomic DNA; and the protein numbering did not include the signal peptide.

Figure 4. Kinetic measurement of thrombin-induced fibrinopeptides release from fibrinogen probands and normal control fibrinogen monitored by radioimmunoassay. Experimental procedure was as described in Materials and Methods Section. Impaired fibrinopeptide release was obtained for proband I-1 (A), proband II-1 (B), and proband III-1 (C) fibrinogen, in contrast to the healthy control (D).
Those genetic results were consistent with clinical manifestations and laboratory tests.

3.6. Fibrinopeptide release

The fibrinopeptide release study of samples from fibrinogen was monitored using a radioimmunoassay method. Compared with the normal control, both the rate and extent of FpA release from the propositus was abnormal, particularly at the first 60 seconds. Fibrinopeptide B (FpB) release appeared moderately delayed (Fig. 4).

3.7. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)

MALDI-TOF MS was used to indicate the expression of abnormal chains. The resulting spectra of the fibrinogen in the release database provided with biotyping software. The spectral peaks are shown in Fig. 5. Findings indicated that the abnormal fibrinogen Aα-chain was a 1063.18 Da peptide (GGGVHGPRVVE, Aα12–22). The normal chain was a 1082.23 Da peptide (GGGVRGPRVVE, Aα12–22). This indicated the expression of Aα chain containing the variant peptide.

3.8. Scanning electron microscopy (SEM) of fibrin clots (SEM)

SEM observations of fibrin clots were formed by narrower fibrils than normal fibrin (Fig. 6). Average fibril diameter of normal and probands’ fibrin clots were found to be 217 ± 63 nm and 142 ± 67 nm (mean ± SD), 156 ± 58 nm (mean ± SD), 148 ± 64 nm (mean ± SD), respectively. The fibrils of abnormal fibrins were significantly different from those of healthy controls. The propositus’
fibrin fibers had many small branched fibers with twisted ends and large pores compared with healthy control.

4. Discussion

This study characterized 3 unrelated Chinese families affected by dysfibrinogenemia, which the probands did not have obvious symptoms of bleeding or thrombosis tendency. AA-chain Arg16His substitution was identified as a causative mutation.

Mutations occurring at the thrombin cleavage site of the fibrinogen alpha chain Arg16-Gly17 are a common cause of the disease.[7] Similar results were reported by Casini et al.[19]: FGA mutations affecting residue Arg16 (i.e., Arg16His and Arg16Cys) at the FpA thrombin cleavage site were frequent in 13.9% and 8.9% of patients, respectively.[24] The results indicate that the substitution of the AA-chain residue Arg16His can prevent thrombin cleavage of the scissile AA-Arg16-Gly17 bond, thus delaying the release of FpA and disrupting of the initial alignment of fibrin monomers into protofibrils, and then these changes can impair the subsequent fibrin clot formation.

Mass spectrometric analysis is very useful technique that can reveal the expression of an abnormal chains with the mutation in AA-chain Arg16His. We detected a 1082.23 Da signal corresponding to the GGGVRGPRVVE (AA-12-22) peptide of the normal fibrinogen AA chain. Anomalous peptide peaks were present at 1063.18Da GGGVHGPRVVE peptide (AA-12-22) of an abnormal fibrinogen AA-chain as observed in the MS spectrum (Fig. 5).

Molecular defects in fibrinogen may result in impair the release of fibrinopeptides. This is consistent with structural studies of abnormal fibrinogen. The specific cleavage of fibrinogen AA Arg16-Gly17 bond results in release of fibrinopeptides A (FpA). The data from fibrinopeptide release demonstrated that both the rate and extent of FpA release from the propositus was abnormal while compared with the normal control, particularly at the first 60 seconds. FpB release appeared moderately delayed. Stucki et al.[25] and Mathonnet et al.[26] also reported that FpA was released at a slow rate. Lewis et al.[27] indicated that the prior release of FpA is essential to the subsequent release of FpB. Kotlin et al.[23] showed another point of view that some FpB were released from the fibrinogen molecules without any prior release of FpA. Andes et al.[28] also suggested that the cleavage and release of FpB are in some way dependent upon the prior release of FpA and the polymerization of fibrinogen. On the basis of these observations, Blomback et al.[29] proposed that removal of FpA leads to change in conformation of the fibrinogen molecule and that these conformational changes in turn increase the cleavability of FpB.

The removal of FpA exposes a polymerization site knobs “A” that initiates polymerization by docking to a hole “a” in the D domain of a neighboring molecules.[30] Impaired cleavage of FpA may resulted in delayed fibrin polymerization. It found that a fibrin monomer polymerization curve of the propositus fibrinogen (Fig. 2) showed a longer lag time, shallower slope, and lower final amplitude than healthy controls. The most noticeable delay occurred during the final stages of appearing a fibrin clot. Similar results were obtained by Stucki,[25] Kotlin et al.[11,23] and Mathonnet et al.[26] They all have a common characteristic in thrombin-induced fibrin polymerization which is markedly delayed but the individuals do not exhibit common clinical symptoms.

Figure 6. Scanning electron micrographs of plasma fibrin clots. Clots formed in 33 mL plasma by addition of 1 mL thrombin (2 NIH U/mL, final concentration) for 2 hours. The magnification is the same for all images (bar = 5 μm). SEM images of proband I-1 (A), proband II-1 (B), and proband III-1 (C), and a healthy control individual (D).
Knobs “A”—holes “a” interactions give rise to form double-stranded twisting fibrils in a staggered overlapping end-to-middle domain arrangement. Fibrils undergo lateral associations to make up the physical meshwork of the coagulum. The initiating event in normal clot formation is the release of FPA, which exposes 1 set of polymerization domains. The aberrant alpha-chain lacking the amino acids of FpA may impact the first steps of fibrin polymerization, which are driven by knobs “A”—holes “a” interactions, and thus lead to the variety of the network structure. We found that the clotting ability of propositus’ fibrinogen is reduced in comparison with the healthy control. SEM showed that the morphology of the patients’ clots were different from that of the healthy control. The propositus’ fibrin fibers had many small branched fibers with twisted ends and large pores compared with healthy control.

It is not surprising that patients with AαArg16His dysfibrinogenemia are mostly asymptomatic. However, patients with the same mutation have also been reported to have a tendency toward severe bleeding and postpartum DIC. That is why CD clinical manifestation shows extensive heterogeneity and usually very mild, was reported in about 20% of the published cases. Kotlin et al. noted that it is very important that patients should be advised the possible risks of bearing this mutation so they can plan for their futures.

In conclusion, patients with CD deserve better predictive tests for clinical complications. Structure–function analysis of this mutant can provide diverse insight into the variable roles of fibrinogen and may ultimately lead to better patient care once the clinical implications of this mutation are understood.

Acknowledgments

We would like to thank the Department of hematology and Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, China. We are grateful to all family members for their participation in this study.

References

[1] Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006;4:1215–29.
[2] Asselta R, Robusto M, Plate M, et al. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res 2015;136:168–74.
[3] Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol 2007;14:236–41.
[4] Tirror GA, Brennan SO, Stangou AJ, et al. Human plasma fibrinogen is synthesized in the liver. Blood 2007;109:1971–4.
[5] Bin Q, Liang F, Ou DY, et al. Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes. Blood Coagul Fibrinolysis 2015;26:364–71.
[6] Hill M, Dolan G. Diagnosis, clinical features and molecular assessment of the dysfibrinogenemias. Haemaphilia 2008;14:889–97.
[7] Casini A, De Maistre E, Casini-Stuppi V, et al. Fibrinogen gene variation II: a new congenitally abnormal fibrinogen alpha chain (Gly17Aasp) with a review of similar mutations resulting in abnormal knob A. Blood Coagul Fibrinolysis 2014;25:280–2.
[8] Hua B, Li K, Lee A, et al. Coexisting congenital dysfibrinogenemia with a novel mutation in fibrinogen gamma chain (gamma322 Phe→Ile, Fibrinogen Beijing) and haemophilia B in a family. Haemaphilia 2015;21:846–51.
[9] Kotlin R, Reicheltova Z, Suttar J, et al. Two novel fibrinogen variants in the C-terminus of the Bbeta-chain: fibrinogen Rokycany and fibrinogen Znojmo. J Thromb Thrombolysis 2010;30:311–8.
[10] Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenemiaa. Br J Haematol 2001;114:249–57.
[11] Mieszbach W, Scharrer I, Hetschen A, et al. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis 2010;21:35–40.
[12] de Moerlooze P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39:85S–95.
[13] Zdziarska J, Iwaniec T, Undas A, et al. Bleeding tendency and prolonged wound healing in a patient with AαArg16His dysfibrinogenemia: fibrinogen Krakow IV. Thromb Res 2012;129:332–3.
[14] Yan J, Deng D, Luo M, et al. Dysfibrinogenemia in a patient undergoing artificial abortion after misdiagnosis and review of the literature. Clin Chim Acta 2015;447:S6–9.
[15] Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151–63.
[16] Shapiro SE, Phillips E, Manning RA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenemia. Br J Haematol 2013;160:220–7.
[17] Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res 2012;130(Suppl 2):S7–11.
[18] Casini A, Neerman-Arbez M, Arians RA, et al. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015;13:909–19.
[19] Casini A, Blunden M, Lebretot A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015;125:53–61.
[20] Gralnick HR, Grivelser HM, Scanoff JR, et al. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest 1971;50:1819–39.
[21] Velusamy P, Pachaiappan R, Christopher M, et al. Isolation and identification of a novel fibrinolytic Bacillus tequilensis CWD-67 from damping soils enriched with poultry wastes. J Gen Appl Microbiol 2013;59:241–7.
[22] Kotlin R, Chytirova M, Suttar J, et al. A novel fibrinogen variant—Praha I: hypofibrinogenemia associated with gamma Gly351Ser substitution. Eur J Haematol 2007;78:410–6.
[23] Kotlin R, Chytirova M, Suttar J, et al. Fibrinogen Novy Jicin and Praha II: cases of hereditary AαArg16His and A alpha 16 Arg→His dysfibrinogenemia. Thromb Res 2007;121:75–84.
[24] Loreth RM, Meyer M, Albert FW. Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg→cys substitution. Haemostasis 2001;31:12–7.
[25] Stucki B, Zehnhausern R, Biedermann B, et al. Fibrinogens Bern IV, Bern V and Milano Xl: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain. Blood Coagul Fibrinolysis 1999;10:93–9.
[26] Mathonnet F, Peltier JY, Roda L, et al. Three new cases of dysfibrinogenemia: Poissy III, Saint-Germain I and Tahiti. Thromb Res 2001;103:201–7.
[27] Lewis SD, Shields PP, Shafer JA. Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin. J Biol Chem 1985;260:10192–9.
[28] Andes WA, Chavin SI, Beltran G, et al. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality. Thromb Res 1982;2:541–50.
[29] Blomback M, Blomback B, Mammen EF, et al. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature 1997;388:134–7.
[30] Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894–904.
[31] Vorjohann S, Fish RJ, Biron-Andreac M, et al. Hypodysfibrinogenemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob ‘A’. Thromb Haemost 2010; 104:990–7.
[32] Mathonnet F, Guillou L, Desthu E, et al. Fibrinogen Poissy I: a new case of the A alpha Arg 16 His fibrinogen variant. Blood Coagul Fibrinolysis 1997;8:441–4.